Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population
•Japanese children aged 3–6 years had low-avidity anti-PT IgG with low titers.•Vaccine-induced anti-PT IgG avidity might rapidly wane after ACVs vaccination.•Additional booster vaccination is required for children aged 3–6 years in Japan. To gain insights into the current Japanese pertussis immuniza...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2019-04, Vol.37 (18), p.2463-2469 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2469 |
|---|---|
| container_issue | 18 |
| container_start_page | 2463 |
| container_title | Vaccine |
| container_volume | 37 |
| creator | Fumimoto, Rei Otsuka, Nao Sunagawa, Tomimasa Tanaka-Taya, Keiko Kamiya, Hajime Kamachi, Kazunari |
| description | •Japanese children aged 3–6 years had low-avidity anti-PT IgG with low titers.•Vaccine-induced anti-PT IgG avidity might rapidly wane after ACVs vaccination.•Additional booster vaccination is required for children aged 3–6 years in Japan.
To gain insights into the current Japanese pertussis immunization schedule, we examined the distributions of antibody titers and avidities to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 460 Japanese healthy subjects (aged 1–60 years) based on age category. Our avidity enzyme-linked immunosorbent assays revealed that young children aged 1–2 years, which corresponded to ages after receiving primary and/or booster pertussis vaccinations, had relatively high-avidity anti-PT IgG (mean avidity index [AI], 40.5%) compared with other age groups (AI, 26.5–31.9%); however, they had relatively low-avidity anti-FHA IgG (AI, 41.8%). In contrast, children aged 3–6 years had both low-avidity anti-PT IgG (AI, 26.5%) and low-avidity anti-FHA IgG (AI, 40.4%). A significant age-related difference in anti-PT IgG avidity was observed between children aged 1–2 years and 3–6 years (P |
| doi_str_mv | 10.1016/j.vaccine.2019.03.055 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2201715779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X19303895</els_id><sourcerecordid>2204223298</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-5e26c5f31dc04e549f73d2eb7fd38b39eb7c32aa8d4b1c7699eb73df22f8d973</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi1ERZfCTwBF4sIlqT_iTXxCVcWnKvXSQ2-WY4-3XiV2sJ0Ve-Kv47ALBy6c7Jl5ZubVvAi9IbghmGyv981Bae08NBQT0WDWYM6foQ3pO1ZTTvrnaIPptq1bgh8v0cuU9hhjzoh4gS4ZFqxE_Qb9vNlBHWFUGUxlnLUQwWtIlfOV8tkNwRwrdXDGZVeyOVQzxLyk5Nbgx2_KVNaNagKfw5KqJ5jUbjcu2flSXYGSUmN-Olbf1Kw8JKjmMC9lpQv-Fbqwakzw-vxeoYdPHx9uv9R395-_3t7c1brlItcc6FZzy4jRuAXeCtsxQ2HorGH9wET5aUaV6k07EN1txZphxlJqeyM6doXen8bOMXxfIGU5uaRhHIueIlrScsSO8K4TBX33D7oPS_RF3Eq1lDIq-kLxE6VjSCmClXN0k4pHSbBcDZJ7eTZIrgZJzGQxqPS9PU9fhgnM364_jhTgwwmAco2DgyiTdqslxkXQWZrg_rPiFxdSpwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2204223298</pqid></control><display><type>article</type><title>Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Fumimoto, Rei ; Otsuka, Nao ; Sunagawa, Tomimasa ; Tanaka-Taya, Keiko ; Kamiya, Hajime ; Kamachi, Kazunari</creator><creatorcontrib>Fumimoto, Rei ; Otsuka, Nao ; Sunagawa, Tomimasa ; Tanaka-Taya, Keiko ; Kamiya, Hajime ; Kamachi, Kazunari</creatorcontrib><description>•Japanese children aged 3–6 years had low-avidity anti-PT IgG with low titers.•Vaccine-induced anti-PT IgG avidity might rapidly wane after ACVs vaccination.•Additional booster vaccination is required for children aged 3–6 years in Japan.
To gain insights into the current Japanese pertussis immunization schedule, we examined the distributions of antibody titers and avidities to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 460 Japanese healthy subjects (aged 1–60 years) based on age category. Our avidity enzyme-linked immunosorbent assays revealed that young children aged 1–2 years, which corresponded to ages after receiving primary and/or booster pertussis vaccinations, had relatively high-avidity anti-PT IgG (mean avidity index [AI], 40.5%) compared with other age groups (AI, 26.5–31.9%); however, they had relatively low-avidity anti-FHA IgG (AI, 41.8%). In contrast, children aged 3–6 years had both low-avidity anti-PT IgG (AI, 26.5%) and low-avidity anti-FHA IgG (AI, 40.4%). A significant age-related difference in anti-PT IgG avidity was observed between children aged 1–2 years and 3–6 years (P < 0.05); however, the difference in anti-FHA IgG avidity was not significant. The anti-PT IgG avidity was positively correlated with the antibody titer, especially among children aged 1–15 years (rs = 0.508–0.685; P < 0.01), indicating that the avidity of vaccine-induced anti-PT IgG decreases with decreasing IgG antibody titer to PT. Our findings strongly suggest that vaccine-induced anti-PT IgG avidity rapidly wanes after vaccination, but this is not observed for anti-FHA IgG avidity. Because children aged 3–6 years have both low-quantity and low-quality antibodies against PT, an additional booster vaccination with acellular pertussis vaccines is required for such children in Japan.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2019.03.055</identifier><identifier>PMID: 30930008</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acellular pertussis vaccine ; Age ; Age groups ; Antibody avidity ; Antibody titer ; Antigens ; Avidity ; Children ; Filamentous hemagglutinin ; Hemagglutinins ; IgG antibody ; Immunization ; Immunoassays ; Immunoglobulin G ; Immunoglobulins ; Infectious diseases ; Personal information ; Pertussis ; Pertussis toxin ; Schedules ; Streptococcus infections ; Teenagers ; Toxins ; Vaccines ; Whooping cough</subject><ispartof>Vaccine, 2019-04, Vol.37 (18), p.2463-2469</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><rights>2019. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-5e26c5f31dc04e549f73d2eb7fd38b39eb7c32aa8d4b1c7699eb73df22f8d973</citedby><cites>FETCH-LOGICAL-c459t-5e26c5f31dc04e549f73d2eb7fd38b39eb7c32aa8d4b1c7699eb73df22f8d973</cites><orcidid>0000-0003-3204-2638 ; 0000-0001-5259-1744</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X19303895$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30930008$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fumimoto, Rei</creatorcontrib><creatorcontrib>Otsuka, Nao</creatorcontrib><creatorcontrib>Sunagawa, Tomimasa</creatorcontrib><creatorcontrib>Tanaka-Taya, Keiko</creatorcontrib><creatorcontrib>Kamiya, Hajime</creatorcontrib><creatorcontrib>Kamachi, Kazunari</creatorcontrib><title>Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Japanese children aged 3–6 years had low-avidity anti-PT IgG with low titers.•Vaccine-induced anti-PT IgG avidity might rapidly wane after ACVs vaccination.•Additional booster vaccination is required for children aged 3–6 years in Japan.
To gain insights into the current Japanese pertussis immunization schedule, we examined the distributions of antibody titers and avidities to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 460 Japanese healthy subjects (aged 1–60 years) based on age category. Our avidity enzyme-linked immunosorbent assays revealed that young children aged 1–2 years, which corresponded to ages after receiving primary and/or booster pertussis vaccinations, had relatively high-avidity anti-PT IgG (mean avidity index [AI], 40.5%) compared with other age groups (AI, 26.5–31.9%); however, they had relatively low-avidity anti-FHA IgG (AI, 41.8%). In contrast, children aged 3–6 years had both low-avidity anti-PT IgG (AI, 26.5%) and low-avidity anti-FHA IgG (AI, 40.4%). A significant age-related difference in anti-PT IgG avidity was observed between children aged 1–2 years and 3–6 years (P < 0.05); however, the difference in anti-FHA IgG avidity was not significant. The anti-PT IgG avidity was positively correlated with the antibody titer, especially among children aged 1–15 years (rs = 0.508–0.685; P < 0.01), indicating that the avidity of vaccine-induced anti-PT IgG decreases with decreasing IgG antibody titer to PT. Our findings strongly suggest that vaccine-induced anti-PT IgG avidity rapidly wanes after vaccination, but this is not observed for anti-FHA IgG avidity. Because children aged 3–6 years have both low-quantity and low-quality antibodies against PT, an additional booster vaccination with acellular pertussis vaccines is required for such children in Japan.</description><subject>Acellular pertussis vaccine</subject><subject>Age</subject><subject>Age groups</subject><subject>Antibody avidity</subject><subject>Antibody titer</subject><subject>Antigens</subject><subject>Avidity</subject><subject>Children</subject><subject>Filamentous hemagglutinin</subject><subject>Hemagglutinins</subject><subject>IgG antibody</subject><subject>Immunization</subject><subject>Immunoassays</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Infectious diseases</subject><subject>Personal information</subject><subject>Pertussis</subject><subject>Pertussis toxin</subject><subject>Schedules</subject><subject>Streptococcus infections</subject><subject>Teenagers</subject><subject>Toxins</subject><subject>Vaccines</subject><subject>Whooping cough</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU1v1DAQhi1ERZfCTwBF4sIlqT_iTXxCVcWnKvXSQ2-WY4-3XiV2sJ0Ve-Kv47ALBy6c7Jl5ZubVvAi9IbghmGyv981Bae08NBQT0WDWYM6foQ3pO1ZTTvrnaIPptq1bgh8v0cuU9hhjzoh4gS4ZFqxE_Qb9vNlBHWFUGUxlnLUQwWtIlfOV8tkNwRwrdXDGZVeyOVQzxLyk5Nbgx2_KVNaNagKfw5KqJ5jUbjcu2flSXYGSUmN-Olbf1Kw8JKjmMC9lpQv-Fbqwakzw-vxeoYdPHx9uv9R395-_3t7c1brlItcc6FZzy4jRuAXeCtsxQ2HorGH9wET5aUaV6k07EN1txZphxlJqeyM6doXen8bOMXxfIGU5uaRhHIueIlrScsSO8K4TBX33D7oPS_RF3Eq1lDIq-kLxE6VjSCmClXN0k4pHSbBcDZJ7eTZIrgZJzGQxqPS9PU9fhgnM364_jhTgwwmAco2DgyiTdqslxkXQWZrg_rPiFxdSpwQ</recordid><startdate>20190424</startdate><enddate>20190424</enddate><creator>Fumimoto, Rei</creator><creator>Otsuka, Nao</creator><creator>Sunagawa, Tomimasa</creator><creator>Tanaka-Taya, Keiko</creator><creator>Kamiya, Hajime</creator><creator>Kamachi, Kazunari</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3204-2638</orcidid><orcidid>https://orcid.org/0000-0001-5259-1744</orcidid></search><sort><creationdate>20190424</creationdate><title>Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population</title><author>Fumimoto, Rei ; Otsuka, Nao ; Sunagawa, Tomimasa ; Tanaka-Taya, Keiko ; Kamiya, Hajime ; Kamachi, Kazunari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-5e26c5f31dc04e549f73d2eb7fd38b39eb7c32aa8d4b1c7699eb73df22f8d973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acellular pertussis vaccine</topic><topic>Age</topic><topic>Age groups</topic><topic>Antibody avidity</topic><topic>Antibody titer</topic><topic>Antigens</topic><topic>Avidity</topic><topic>Children</topic><topic>Filamentous hemagglutinin</topic><topic>Hemagglutinins</topic><topic>IgG antibody</topic><topic>Immunization</topic><topic>Immunoassays</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Infectious diseases</topic><topic>Personal information</topic><topic>Pertussis</topic><topic>Pertussis toxin</topic><topic>Schedules</topic><topic>Streptococcus infections</topic><topic>Teenagers</topic><topic>Toxins</topic><topic>Vaccines</topic><topic>Whooping cough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fumimoto, Rei</creatorcontrib><creatorcontrib>Otsuka, Nao</creatorcontrib><creatorcontrib>Sunagawa, Tomimasa</creatorcontrib><creatorcontrib>Tanaka-Taya, Keiko</creatorcontrib><creatorcontrib>Kamiya, Hajime</creatorcontrib><creatorcontrib>Kamachi, Kazunari</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fumimoto, Rei</au><au>Otsuka, Nao</au><au>Sunagawa, Tomimasa</au><au>Tanaka-Taya, Keiko</au><au>Kamiya, Hajime</au><au>Kamachi, Kazunari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2019-04-24</date><risdate>2019</risdate><volume>37</volume><issue>18</issue><spage>2463</spage><epage>2469</epage><pages>2463-2469</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Japanese children aged 3–6 years had low-avidity anti-PT IgG with low titers.•Vaccine-induced anti-PT IgG avidity might rapidly wane after ACVs vaccination.•Additional booster vaccination is required for children aged 3–6 years in Japan.
To gain insights into the current Japanese pertussis immunization schedule, we examined the distributions of antibody titers and avidities to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 460 Japanese healthy subjects (aged 1–60 years) based on age category. Our avidity enzyme-linked immunosorbent assays revealed that young children aged 1–2 years, which corresponded to ages after receiving primary and/or booster pertussis vaccinations, had relatively high-avidity anti-PT IgG (mean avidity index [AI], 40.5%) compared with other age groups (AI, 26.5–31.9%); however, they had relatively low-avidity anti-FHA IgG (AI, 41.8%). In contrast, children aged 3–6 years had both low-avidity anti-PT IgG (AI, 26.5%) and low-avidity anti-FHA IgG (AI, 40.4%). A significant age-related difference in anti-PT IgG avidity was observed between children aged 1–2 years and 3–6 years (P < 0.05); however, the difference in anti-FHA IgG avidity was not significant. The anti-PT IgG avidity was positively correlated with the antibody titer, especially among children aged 1–15 years (rs = 0.508–0.685; P < 0.01), indicating that the avidity of vaccine-induced anti-PT IgG decreases with decreasing IgG antibody titer to PT. Our findings strongly suggest that vaccine-induced anti-PT IgG avidity rapidly wanes after vaccination, but this is not observed for anti-FHA IgG avidity. Because children aged 3–6 years have both low-quantity and low-quality antibodies against PT, an additional booster vaccination with acellular pertussis vaccines is required for such children in Japan.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30930008</pmid><doi>10.1016/j.vaccine.2019.03.055</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3204-2638</orcidid><orcidid>https://orcid.org/0000-0001-5259-1744</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2019-04, Vol.37 (18), p.2463-2469 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2201715779 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Acellular pertussis vaccine Age Age groups Antibody avidity Antibody titer Antigens Avidity Children Filamentous hemagglutinin Hemagglutinins IgG antibody Immunization Immunoassays Immunoglobulin G Immunoglobulins Infectious diseases Personal information Pertussis Pertussis toxin Schedules Streptococcus infections Teenagers Toxins Vaccines Whooping cough |
| title | Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T19%3A52%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Age-related%20differences%20in%20antibody%20avidities%20to%20pertussis%20toxin%20and%20filamentous%20hemagglutinin%20in%20a%20healthy%20Japanese%20population&rft.jtitle=Vaccine&rft.au=Fumimoto,%20Rei&rft.date=2019-04-24&rft.volume=37&rft.issue=18&rft.spage=2463&rft.epage=2469&rft.pages=2463-2469&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2019.03.055&rft_dat=%3Cproquest_cross%3E2204223298%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2204223298&rft_id=info:pmid/30930008&rft_els_id=S0264410X19303895&rfr_iscdi=true |